Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Robatumumab in Relapsed Osteosarcoma or Ewing's Sarcoma
NCT00617890Phase 2Terminated
- Sponsor
- Merck & Co.
- Start
- Feb 2008
- Primary completion
- Aug 2011
01
Overview
A Phase 2 trial of robatumumab in osteosarcoma (OS), Ewing sarcoma, peripheral primitive neuroectodermal tumor (pPNET), sponsored by Merck & Co.. Started Feb 2008; status: terminated.
02
Drugs
robatumumab
03
Conditions
osteosarcoma (OS)Ewing sarcomaperipheral primitive neuroectodermal tumor (pPNET)
Beyond the preview
Go deeper on NCT00617890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00617890.